![]() |
|
|
Vol. 292, Issue 1, 140-149, January 2000
Isis Pharmaceuticals, Inc., Carlsbad Research Center, Carlsbad,
California
Phosphorothioate antisense oligodeoxynucleotides are novel therapeutic
agents designed to selectively and specifically inhibit production of
various disease-related gene products. In vivo pharmacokinetic experiments indicate that these molecules are widely distributed in
many species, with the majority of oligomers accumulating within liver
and kidney. To better understand the metabolism of these agents, we
studied the stability of several phosphorothioate
oligodeoxynucleotides, their congeners, and second generation oligomer
chemistries in rat liver homogenates. To examine metabolism, background
nuclease activity was characterized in whole liver homogenates by using ISIS 1049, a 21-mer phosphodiester oligodeoxynucleotide. Nuclease activity could readily be detected in liver homogenates. Under optimized conditions, the predominant enzymatic activity was
3'-exonucleolytic and could be influenced by pH and ionic conditions.
However, in addition to 3' exonucleases, 5' exo- and endonuclease
activities were also observed. Our data indicate that metabolism of
phosphorothioate oligodeoxynucleotides was more complex than that of
phosphodiesters for many reasons, including phosphorothioate
oligodeoxynucleotide inhibition of nucleases and the presence of
Rp and Sp
stereoisomers. The rate of phosphorothioate metabolism also appeared to
be influenced by sequence, with pyrimidine-rich compounds being
metabolized to a greater extent than purine-rich oligomers. Other
factors affecting stability included oligomer chemistry and length.
Concomitant experiments performed in rats dosed systemically with the
same compounds mimic the activities seen in vitro and suggest that this
liver homogenate system is a valuable model with which to study the
mechanism of metabolism of antisense oligonucleotides.
This article has been cited by other articles:
![]() |
J. Krutzfeldt, S. Kuwajima, R. Braich, K. G. Rajeev, J. Pena, T. Tuschl, M. Manoharan, and M. Stoffel Specificity, duplex degradation and subcellular localization of antagomirs Nucleic Acids Res., May 14, 2007; 35(9): 2885 - 2892. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Czauderna, M. Fechtner, S. Dames, H. Aygun, A. Klippel, G. J. Pronk, K. Giese, and J. Kaufmann Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells Nucleic Acids Res., June 1, 2003; 31(11): 2705 - 2716. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Geary, O. Khatsenko, K. Bunker, R. Crooke, M. Moore, T. Burckin, L. Truong, H. Sasmor, and A. A. Levin Absolute Bioavailability of 2'-O-(2-Methoxyethyl)-Modified Antisense Oligonucleotides following Intraduodenal Instillation in Rats J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 898 - 904. [Abstract] [Full Text] |
||||